Migra Therapeutics

United States
Johnson, Arkansas, United States, 30303

Company profile

Migra Therapeutics company profile

Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called “stroma,” which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. Early testing of the company’s targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2018-01-01, Year

Headquarters

Postal code
30303
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
2
Last funding
Grant / $51,701 / 2019-01-22
Investors
1
Lead investors
1

Founders and investors

Lead investors

Georgia Research Alliance

Investors

Georgia Research Alliance